High vaccine efficacy seen against RSV A and B subtypes, across age groups among those aged 60 years and older, and for those with coexisting conditions<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Feb. 17, 2023 (HealthDay News) — A single dose of an AS01E<\/sub>-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based candidate vaccine (RSVPreF3 OA) prevents RSV-related acute respiratory infection and lower respiratory tract disease in adults aged 60 years and older, according to a study published in the Feb. 16 issue of the New England Journal of Medicine<\/em>.<\/p>\n Alberto Papi, M.D., from the University of Ferrera and St. Anna University Hospital in Italy, and colleagues conducted an ongoing international, placebo-controlled, phase 3 trial involving adults aged 60 years or older who received a single dose of RSVPreF3 OA or placebo before the RSV season. A total of 24,966 participants were randomly assigned to one dose of vaccine (12,467 participants) or placebo (12,499 participants).<\/p>\n The researchers found that vaccine efficacy against reverse-transcriptase polymerase chain reaction-confirmed RSV-related lower respiratory tract disease was 82.6 percent, with seven and 40 cases in the vaccine and placebo groups, respectively (1.0 versus 5.8 per 1,000 participant-years). Vaccine efficacy was 94.1 and 71.7 percent against severe RSV-related lower respiratory tract disease and RSV-related acute respiratory infection, respectively. Vaccine efficacy was similar against the RSV A and B subtypes (84.6 and 80.9 percent, respectively, for RSV-related lower respiratory tract disease; 71.9 and 70.6 percent, respectively, for RSV-related acute respiratory infection). Vaccine efficacy was high in various age groups and especially among those with coexisting conditions. Most adverse events reported were transient, with mild-to-moderate severity, although the vaccine was more reactogenic than placebo.<\/p>\n “The RSVPreF3 OA vaccine provided protection across the clinical spectrum of RSV disease, from mild upper respiratory tract infection to severe lower respiratory tract disease,” the authors write.<\/p>\n The study was funded by GlaxoSmithKline Biologicals, the manufacturer of the RSVPreF3 OA vaccine.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n